SCHEMBL6470122

SCHEMBL6470122

COc1ccc(C)c2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(C)cc(C)c4n3)nc(C)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.35
TP53 P04637 1/20 0.35
STAT1 P42224 1/20 0.35
MAPT P10636 6/20 0.33
POLB P06746 3/20 0.33
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.33
SYK P43405 1/20 0.33
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.30
CTNNB1 P35222 1/20 0.30
TCF7L2 Q9NQB0 1/20 0.30
MEN1 O00255 1/20 0.30
CTSL P07711 1/20 0.30
CRHBP P24387 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
CRHR2 Q13324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465607 0.95 STAT3 (0.35) STAT3TP53STAT1MAPTPOLB
SCHEMBL6467985 0.89 POLB (0.41) POLBKDM4EGAAALDH1A1HSD17B10
SCHEMBL6470120 0.86 STAT3 (0.36) STAT3TP53STAT1MAPTPOLB
SCHEMBL6469269 0.86 POLB (0.37) POLBKDM4EGAA
SCHEMBL6470303 0.85 KMT2A (0.40) TP53MAPTPOLBGAAMAPK1
SCHEMBL6466279 0.85 MAPT (0.33) STAT3TP53STAT1MAPTKDM4E
SCHEMBL6469547 0.84 MAPT (0.38) STAT3TP53STAT1MAPTPOLB
Trifluoroacetic Acid SCHEMBL6470121 0.84 STAT3 (0.35) STAT3TP53STAT1MAPTPOLB
SCHEMBL6467957 0.83 STAT3 (0.39) STAT3TP53STAT1MAPTPOLB
SCHEMBL6467851 0.82 MAPT (0.36) STAT3TP53STAT1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB STAT3 3341/4885TP53 1339/4885STAT1 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.